News of Note—Kite IND, RXi I-O targets and Mitobridge DMD test

Kite's IND, RXi's I-O picks and Mitobridge phase 1.

Kite Pharma, which in a tight race with Novartis to gain U.S. approval for the first-ever CAR-T med later this year, said it has submitted an IND app with the FDA for a Phase 1, first-in-human trial of KITE-585, another of its CAR-T therapies, to target B-cell maturation antigen (BCMA) in patients with relapsed/refractory multiple myeloma. Release

> RNAi company RXi Pharmaceuticals said it has picked two self-delivering RNAi (sd-rxRNA) compounds from its immuno-oncology pipeline for preclinical development. The compounds, RXI-762 and RXI-804, suppress the expression of immune checkpoint proteins PD-1 and TIGIT. Statement

Mitobridge says it has hit a “key milestone” with the start of the first-in-human Phase 1 test of its PPAR-delta modulator, MA-0211 in healthy volunteers, which will provide the basis for future studies in Duchenne Muscular Dystrophy patients. Release


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Suggested Articles

Sumitovant CEO Myrtle Potter discusses the $3 billion Roivant-Sumitomo deal, her role at Sumitovant and what's up in 2020.

The FDA approved a new, tiny pacemaker from Medtronic that does not require the wiring of separate electrodes between the implant and the heart.

Antibiotics player Summit Therapeutics is gearing up for a new clinical trial of its lead asset, an antibiotic for Clostridium difficile infection.